Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Component 2: Core Viral Hepatitis Prevention Activities

Reporting Agency

Reporting jurisdiction	
Contact name (person completing form)	
Contact phone number (xxx-xxx-xxxx)	
Contact email address	
Additional contact name(s) (if applicable)	
Additional contact phone number(s) (xxx-xxx-xxxx)	
Additional contact email address(es)	
Date of report submission (MM/DD/YYYY)	
Reporting Period	Select one
(Complete this form with information from	Year 1
Reporting Period selected)	□ Year 2
	Year 3
	Year 4
	□ Year 5

2.1—Support viral hepatitis elimination planning and surveillance, and maximize access to testing, treatment, and prevention

Measures 2.1.1.a - 2.1.1.b

- Establishment and maintenance of a viral hepatitis elimination technical advisory committee (or coalition) with membership to support jurisdictional viral hepatitis elimination planning
- Conduct at least two meetings per year of the viral hepatitis elimination technical advisory committee (or coalition)

Have you established a viral hepatitis	Select one	
elimination technical advisory committee	Completed	Not started
(or coalition) to support viral hepatitis elimination planning?	In progress	
Identify the stakeholder groups	Public health	Laboratories
represented on this committee (or	Corrections	Community-based organizations
coalition). (select all that apply)	 Criminal justice, law enforcement 	 Local harm reduction coalition members
	Medicaid	Non-profit/advocacy groups
	Injury prevention services	People with viral hepatitis lived
	Substance use and mental	experience
	health services	Other, specify:
	Healthcare providers	>
	HIV care providers	>
	Hospitals	□ N/A (committee not established)

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Does the committee (or coalition) plan to support elimination		Hepatitis C	□ N/A (committee
planning for hepatitis C and/or hepatitis B?		Hepatitis B	not established)
(select all that apply)			
During this reporting period, when did the	ring this reporting period, when did the >		
<pre>committee (or coalition) meet? (MM/DD/YYYY) ></pre>		>	
	N/A (committee not establish	ied)	
If the committee (or coalition) met during this reporting period, please		Select one	
submit a copy of meeting agenda(s) with the APR.		Submitted	Not submitted
		□ N/A (committee	e not established)

Measure 2.1.1.c

• Development and maintenance of a viral hepatitis elimination plan with support from the technical advisory committee (or coalition)

Have you developed a viral hepatitis elimination plan as part	Select one
of this cooperative agreement?	Completed Not started
	In progress
Does it contain plans for elimination of hepatitis C and/or	□ Hepatitis C □ N/A (plan not started)
hepatitis B? (select all that apply)	Hepatitis B
If the viral hepatitis elimination plan is completed, please	Select one
submit a copy with the APR.	Submitted D Not submitted
	N/A (plan not started)

Measures 2.1.2.c, 2.1.4.a

- The jurisdictional viral hepatitis elimination plan addresses recommendations for increasing HCV RNA reflex testing
- The jurisdictional viral hepatitis elimination plan addresses provider training in prescribing hepatitis C and hepatitis B treatment

Does your viral hepatitis elimination plan address recommendations for increasing HCV RNA reflex testing?	Select one Yes No	□ N/A (plan not started)
Does your viral hepatitis elimination plan address provider training in prescribing hepatitis C treatment?	Select one Yes No	□ N/A (plan not started)
Does your viral hepatitis elimination plan address provider training in prescribing hepatitis B treatment?	Select one Yes No	□ N/A (plan not started)

Measures 2.1.2.a - 2.1.2.b

- CLIA-certified laboratories that conduct testing for at least 80% of all anti-HCV results identified in the jurisdiction
- The proportion conducting HCV RNA reflex testing was assessed; feedback with recommendations conducted

Have you worked with your surveillance and/or epidemiology	Select one
teams to identify the total number of CLIA-certified laboratories in	□ Yes
your jurisdiction that report hepatitis C antibody testing results?	□ No

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Of those, have you selected the subset that reports at least 80% of	Select one	
the hepatitis C antibody testing results in your jurisdiction?	🗆 Yes	□ N/A (labs not identified)
	🗆 No	
Of the subset, have you performed a needs assessment to identify	Select one	
key barriers and challenges to increasing HCV RNA reflex testing?	🗆 Yes	□ N/A (labs not identified)
	🗆 No	
What proportion of the subset is conducting HCV RNA reflex	Select one	
testing?	%:	□ N/A (labs not identified)
	Unknown	
Have you provided recommendations to increase HCV RNA reflex	Select one	
testing?	🗆 Yes	□ N/A (labs not assessed)
	🗆 No	

Measures 2.1.3.a - 2.1.3.b

- The top 5 highest volume health systems in the jurisdiction identified
- The proportion of health systems promoting routine HCV and HBV testing assessed; feedback with recommendations was conducted

What are the top 5 highest volume	1.		
health systems in your jurisdiction?	2.		
	3.		
	4.		
	5.		
	🗆 Unknown		
Have you assessed how many of thes	e health systems are	Select one	
promoting routine HCV testing?		Completed	Not started
		In progress	
If so, what percent of health systems	are promoting routine HCV	%:	
testing?		🗆 Unknown	N/A (health systems not assessed)
Have you assessed how many of these health systems are		Select one	
promoting routine HBV testing?		Completed	Not started
		In progress	
If so, what percent of health systems	are promoting routine HBV	%:	
testing?		🗆 Unknown	□ N/A (health systems not assessed)
Have you provided feedback to the top 5 highest volume health systems with recommendations on promoting routine HCV and/ or HBV testing?		Select one	
		🗆 Yes	N/A (health systems not assessed)
		🗆 No	

Use this space if needed	
to provide additional information	
related to Section 2.1	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Was Section 2.2 funded?Select oneNoNOTE: Stop here if not fundedYes

2.2—Increase access to hepatitis C and/or hepatitis B testing and referral to care in high-impact settings

Measures 2.2.2.a - 2.2.2.b

- Jurisdiction established relationship with partners in high-impact settings to identify high priority facilities for expansion of testing for HCV and/or HBV in high-impact settings, by setting type (syringe services programs, substance use disorder treatment programs, correctional facilities, emergency departments, hospital-based programs, sexually transmitted disease clinics, homeless services, health centers, other)
- Number of clients seen, by setting

Setting	Relationship established to expand HCV testing	Relationship established to expand HBV testing	Number of clients seen during this reporting period
Setting 1	Select one	Select one	>
Type: >	□ Yes	🗆 Yes	Unknown
If other, specify:	🗆 No	🗆 No	🗆 N/A
>			
Name: >			
Setting 2	Select one	Select one	>
Type: >	🗆 Yes	🗆 Yes	Unknown
If other, specify:	🗆 No	🗆 No	□ N/A
>			
Name: >			
Setting 3	Select one	Select one	>
Type: >	🗆 Yes	□ Yes	🗆 Unknown
If other, specify:	🗆 No	🗆 No	□ N/A
> Name: >			
Setting 4	Select one	Select one	>
Type: >	□ Yes	□ Yes	
If other, specify:			
>	🗆 No	□ No	□ N/A
Name: >			
Setting 5	Select one	Select one	>
Type: >	🗆 Yes	🗆 Yes	🗆 Unknown
If other, specify:	□ No	□ No	□ N/A
>		,	
Name: >			
Setting 6	Select one	Select one	>

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

		□ Yes	
Type: >	🗆 Yes	🗆 No	Unknown
If other, specify:	🗆 No		□ N/A
>			
Name: >			
Setting 7	Select one	Select one	>
Type: >	🗆 Yes	🗆 Yes	Unknown
If other, specify:	🗆 No	🗆 No	□ N/A
>			
Name: >			
Setting 8	Select one	Select one	>
Type: >	🗆 Yes	□ Yes	Unknown
If other, specify:	🗆 No	🗆 No	□ N/A
>			
Name: >			
Total number of settings:			TOTAL: >
>			

Measures 2.2.2.c - 2.2.2.f, 2.2.3.a

- Number of clients screened for hepatitis C (anti-HCV), by setting
- Number of clients positive for anti-HCV, by setting
- Number of clients tested for HCV RNA, by setting
- Number of clients positive for HCV RNA, by setting
- Number of clients positive for HCV RNA linked to treatment, by setting

	During this reporting period, number of:						
Setting	Clients screened for hepatitis C (anti-HCV)	Clients positive for anti-HCV	Clients tested for HCV RNA	Clients positive for HCV RNA	Clients positive for HCV RNA linked to hepatitis C treatment		
Setting 1	>	>	>	>	>		
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown		
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A	🗆 N/A		
>							
Name: >							
Setting 2	>	>	>	>	>		
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown		
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A	□ N/A		
>							
Name: >							
Setting 3	>	>	>	>	>		

				🗆 Unknown	
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	□ N/A	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A		□ N/A
>					
Name: >					
Setting 4	>	>	>	>	>
Type: >	🗆 Unknown				
If other, specify:	□ N/A				
>					
Name: >	>	>	>	>	>
Setting 5 Type: >					
If other, specify:	□ Unknown				
>	□ N/A				
Name: >					
Setting 6	>	>	>	>	>
Type: >	🗆 Unknown				
If other, specify:	□ N/A				
>	,				
Name: >					
Setting 7	>	>	>	>	>
Type: >	🗆 Unknown				
If other, specify:	□ N/A				
>					
Name: >					
Setting 8	>	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown	Unknown
If other, specify:	□ N/A				
> Name: >					
Total number of settings:	TOTAL: >				
>					

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Measures 2.2.2.g - 2.2.2.h, 2.2.3.b

- Number of clients screened for hepatitis B, by setting
- Number of clients positive for HBsAg, by setting
- Number of clients positive for HBsAg linked to care, by setting

	During this reporting period, number of:						
Setting	Clients screened for hepatitis B	Clients positive for HBsAg	Clients positive for HBsAg linked to hepatitis B care				
Setting 1	>	>	>				
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown				
If other, specify:	□ N/A	□ N/A	□ N/A				
>							
Name: >							
Setting 2	>	>	>				
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown				
If other, specify:	🗆 N/A	□ N/A	□ N/A				
> Name: >							
Setting 3	>	>	>				
Type: >	⊂ □ Unknown		□ Unknown				
If other, specify:							
>	□ N/A	□ N/A	□ N/A				
Name: >							
Setting 4	>	>	>				
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown				
If other, specify:	D N/A	□ N/A	□ N/A				
>	,.		,				
Name: >							
Setting 5	>	>	>				
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown				
If other, specify:	🗆 N/A	□ N/A	🗆 N/A				
>							
Name: >							
Setting 6	>	>	>				
Type: > If other, specify:							
>	□ N/A	□ N/A	□ N/A				
Name: >							
Setting 7	>	>	>				
Type: >	🗆 Unknown	🗆 Unknown	□ Unknown				
If other, specify:							
>							
Name: >							

Setting 8	>	>	>
Type: >	🗆 Unknown	Unknown	Unknown
If other, specify:	□ N/A	□ N/A	□ N/A
>			
Name: >			
Total number of settings:	TOTAL: >	TOTAL: >	TOTAL: >
>			

Use this space	
if needed	
to provide	
additional	
information	
related to	
Section 2.2	
	1

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Was Section 2.3 funded?	Select one	□ No NOTE: Stop here if not funded	□ Yes

2.3—Improve access to services preventing viral hepatitis and other bloodborne infections among people who inject drugs (PWID)

Measures 2.3.3.a - 2.3.3.d

• Number of hepatitis A vaccination doses administered to clients in the high-impact settings, by setting

• Number of clients in the high-impact settings who completed hepatitis A vaccination series, by setting

• Number of hepatitis B vaccination doses administered to clients in the high-impact settings, by setting

• Number of clients in the high-impact settings who completed hepatitis B vaccination series, by setting

	D	ouring this reporting	g period, number	of:
Setting	Hepatitis A vaccination doses administered	Clients who completed hepatitis A vaccination series	Hepatitis B vaccination doses administered	Clients who completed hepatitis B vaccination series
Setting 1	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
>				
Name: >				
Setting 2	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
>				
Name: >	>	>	>	>
Setting 3			*	
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
> Name: >				
Setting 4	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
>				
Name: >				
Setting 5	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	🗆 N/A	🗆 N/A	□ N/A	🗆 N/A
>				
Name: >				
Setting 6	>	>	>	>

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

			🗆 Unknown	
Type: >	🗆 Unknown	🗆 Unknown	□ N/A	🗆 Unknown
If other, specify:	□ N/A	□ N/A		□ N/A
>				
Name: >				
Setting 7	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
>				
Name: >				
Setting 8	>	>	>	>
Type: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	🗆 Unknown
If other, specify:	□ N/A	□ N/A	□ N/A	□ N/A
>				
Name: >				
Total number of settings:	TOTAL: >	TOTAL: >	TOTAL: >	TOTAL: >
>				

Measures 2.3.1.a - 2.3.1.d, 2.3.2.a

- Number of syringe services programs (SSPs) in the jurisdiction
- Number of visits in the jurisdiction, by SSP
- Number of unduplicated SSP clients in the jurisdiction, by SSP
- Mean (median) syringe coverage rates, by SSP
- Number of clients linked to substance use disorder treatment by SSPs in the jurisdiction, by SSP

	During th	is reporting period, r	number of:	
Syringe services programs (SSPs) in jurisdiction	Client visits	Unduplicated SSP clients	Clients linked to substance use disorder treatment	Mean (median) syringe coverage rates during this reporting period
SSP 1 Name:	> □ Unknown □ N/A	> □ Unknown □ N/A	> □ Unknown □ N/A	>
SSP 2 Name: >	> □ Unknown □ N/A	> □ Unknown □ N/A	> □ Unknown □ N/A	>
SSP 3 Name: >	> Unknown N/A	> unknown N/A	> □ Unknown □ N/A	>

SSP 4	>	>	>	>
Name:				
>			□ Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 5	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 6	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	🗆 N/A	□ N/A	🗆 N/A	
SSP 7	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 8	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A	□ N/A	□ N/A	
SSP 9	>	>	>	>
Name:	⊂ □ Unknown	⊂ □ Unknown		
>				
	□ N/A			
SSP 10 Name:	>	>	>	>
>	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 11	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 12	>	>	>	>
Name: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	🗆 N/A	
SSP 13	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A	□ N/A	□ N/A	
SSP 14	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A			
SSP 15	>	>	>	>
Name:	⊂ □ Unknown	⊂ □ Unknown	⊂ □ Unknown	
>				
	□ N/A	□ N/A	□ N/A	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

SSP 28	>	>	>	>
	□ N/A	□ N/A	□ N/A	
>				
SSP 27 Name:	>	>	>	>
	□ N/A	□ N/A	□ N/A	
Name:	🗆 Unknown			
SSP 26 Name:	>			>
	□ N/A	□ N/A	□ N/A	
Name: >	🗆 Unknown	□ Unknown	🗆 Unknown	
SSP 25	>			>
	D N/A	□ N/A	□ N/A	
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
SSP 24	>	>	>	>
	□ N/A	□ N/A	□ N/A	
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
SSP 23 Name:	>	>	>	>
	□ N/A	□ N/A	□ N/A	
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
SSP 22 Name:	>	>	>	>
	□ N/A	□ N/A	□ N/A	
Name:			□ Unknown	
SSP 21 Name:	>	>	>	>
	□ N/A	□ N/A	□ N/A	
>				
SSP 20 Name:	>	>	>	>
	□ N/A	□ N/A	□ N/A	
>	□ Unknown		□ Unknown	
SSP 19 Name:			>	>
CCD 10				
>				
SSP 18 Name:	>	> □ Unknown	>	>
CCD 10				
>				
Name:	□ Unknown	⊂ □ Unknown	□ Unknown	
SSP 17	>	>	>	>
>				
Name:	□ Unknown		□ Unknown	
SSP 16	>	>	>	>

Name:	🗆 Unknown			
>		🗆 Unknown	🗆 Unknown	
SSP 29	<u> </u>	> N/A	> N/A	>
SSP 29 Name:	>			>
>				
	□ N/A	□ N/A	□ N/A	
SSP 30 Name:	>	>	>	>
>	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 31	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	🗆 N/A	🗆 N/A	□ N/A	
SSP 32	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A	□ N/A	□ N/A	
SSP 33	>	>	>	>
Name:	🗆 Unknown	🗆 🗆 Unknown	🗆 Unknown	
>			□ N/A	
SSP 34	>	>	>	>
Name:	□ Unknown	□ Unknown	Unknown	-
>				
	□ N/A	□ N/A	□ N/A	
SSP 35 Name:	>	>	>	>
>	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 36	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	🗆 N/A	□ N/A	□ N/A	
SSP 37	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
·	□ N/A	□ N/A	□ N/A	
SSP 38	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A		□ N/A	
SSP 39	>	>	>	>
Name:	⊂ □ Unknown	⊂ □ Unknown	□ Unknown	
>				
	□ N/A	□ N/A	□ N/A	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

SSP 40	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
>	□ N/A	□ N/A	□ N/A	
SSP 41	>	>	>	>
Name:				
>				
SSP 42	>	>	>	>
Name:	⊂ □ Unknown	□ Unknown	□ Unknown	
>				
CCD 42	>	>	>	>
SSP 43 Name:	∠ Dunknown	^{>} □ Unknown	⊃ □ Unknown	>
>				
CCD 44	□ N/A	□ N/A	□ N/A	
SSP 44 Name:	>	>	>	>
>	□ Unknown	□ Unknown		
	□ N/A	□ N/A	□ N/A	
SSP 45 Name:	>	>	>	>
>				
	□ N/A	□ N/A	□ N/A	
SSP 46 Name:	>	>	>	>
>	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 47	>	>	>	>
Name: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 48	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 49	>	>	>	>
Name: >	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
SSP 50	>	>	>	>
Name:	🗆 Unknown	🗆 Unknown	🗆 Unknown	
	□ N/A	□ N/A	□ N/A	
Total number of SSPs:	TOTAL: >	TOTAL: >	TOTAL: >	Overall mean
>				(median): >

Use this space if needed to provide additional information related to Section 2.3	